BrainStorm Cell Therapeutics Announces Second Quarter 2026 Financial Results and Provides Corporate Update

BrainStorm's cash is nearly exhausted, with no clinical or commercial milestones achieved yet.

What the company is saying

BrainStorm Cell Therapeutics frames itself as a leading developer in adult stem cell therapeutics, emphasizing its preparations for the Phase 3b ENDURANCE trial in ALS. The company highlights the FDA's Special Protocol Assessment as a unique regulatory milestone, presenting it as a differentiator. Leadership changes are foregrounded, notably the appointment of Peter J. Pitts as Executive Chairman and Chief Strategic Regulatory and Policy Officer, with his regulatory background positioned as a strategic asset. Financial updates stress recent capital raises totaling approximately $2.4 million in the first half of 2026, but the language focuses on the act of raising capital rather than sufficiency. The company reiterates its commitment to the ALS community and advancing NurOwn, but provides no evidence of trial initiation or enrollment. The overall tone is neutral but leans on forward-looking statements and regulatory process achievements rather than operational or financial results.

What the data suggests

Financial disclosures show cash, cash equivalents, and restricted cash at just $0.2 million as of June 30, 2026, down sharply from $1.03 million a year earlier. Net loss for Q2 2026 was $3.9 million, up from $2.9 million in Q2 2025, while general and administrative expenses rose from $1.5 million to $2.7 million year-over-year. Research and development spending decreased slightly to $1 million in Q2 2026 from $1.1 million in Q2 2025. Capital raised in the first half of 2026 totaled $2.4 million, but this is insufficient relative to the company’s quarterly net loss and ongoing cash burn. Total current liabilities stand at $12.4 million, vastly exceeding current assets of $316,000, resulting in a stockholders’ deficit of $(11.6) million. No revenue or clinical trial enrollment data is reported, and all clinical progress remains at the preparatory stage. The numbers point to a deteriorating financial position with no immediate operational milestones delivered.

Analysis

The announcement presents a standard quarterly update with a focus on upcoming clinical milestones, leadership changes, and recent capital raises. While the tone is measured, the majority of key claims are forward-looking, centering on the planned Phase 3b ENDURANCE trial, which has not yet begun enrolling patients. The benefits of the trial, including potential regulatory approval and therapeutic impact, are long-dated and contingent on successful execution. The company highlights its capital raises, but the amounts are modest relative to its growing net loss and significant stockholders' deficit, and cash reserves are critically low. There is no evidence of immediate revenue or profitability, and the operational progress is limited to preparatory steps. The narrative inflates the signal by emphasizing regulatory milestones (e.g., Special Protocol Assessment) and leadership appointments as value drivers, despite the lack of near-term financial or clinical catalysts.

Risk flags

• ●Liquidity risk is acute, with only $0.2 million in cash and equivalents as of June 30, 2026, against a quarterly net loss of $3.9 million and current liabilities of $12.4 million. This raises the likelihood of insolvency or the need for highly dilutive financing in the immediate term.
• ●Execution risk is high, as the company has not yet initiated the planned Phase 3b ENDURANCE trial. All clinical milestones remain forward-looking, and there is no evidence of patient enrollment or operational progress beyond preparatory work.
• ●Disclosure risk is present, as the company omits key details such as revenue (if any), cash burn rate projections, and specific timelines for trial initiation. The absence of granular financial and operational data limits investor ability to assess near-term viability.
• ●Capital intensity risk is flagged, with recent capital raises totaling $2.4 million in the first half of 2026 insufficient to cover ongoing losses. The company will likely require significant additional funding, which may be difficult to secure given its deteriorating balance sheet.

Bottom line

BrainStorm Cell Therapeutics is running critically low on cash, with only $0.2 million remaining as of June 30, 2026, and a net loss of $3.9 million in the latest quarter. Despite raising $2.4 million in the first half of 2026, the company’s liabilities and cash burn far outstrip available resources. No clinical or commercial milestones have been achieved, as the Phase 3b ENDURANCE trial remains in the preparatory phase with no patients enrolled. Leadership changes and regulatory process achievements are highlighted, but these do not translate into near-term value or operational progress. The lack of detailed disclosure on trial timelines and financial runway further clouds the outlook. Unless BrainStorm secures substantial new funding or delivers a concrete clinical milestone, the risk of insolvency or severe dilution is high. The most important takeaway is that the company’s financial position is unsustainable without immediate and material external support.

Announcement summary

(OTCQB: BCLI) BrainStorm Cell Therapeutics Inc. announced financial results for the second quarter ended June 30, 2026, and provided a corporate update. The company is completing preparations to initiate the Phase 3b ENDURANCE study of NurOwn in ALS, supported by an FDA-agreed protocol under a Special Protocol Assessment. In July 2026, BrainStorm appointed Peter J. Pitts as Executive Chairman and Chief Strategic Regulatory and Policy Officer. BrainStorm completed private placements totaling $400,000 in May 2026, and together with $2.0 million raised in February 2026, capital raised in first-half 2026 totals approximately $2.4 million. Cash, cash equivalents, and restricted cash were approximately $0.2 million as of June 30, 2026. Research and development expenditures, net, for the second quarter of 2026 were approximately $1 million. Net loss for the second quarter of 2026 was approximately $3.9 million.

Disagree with this article?